

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

RETIREMENT OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF MEDICAL OFFICER (CMO)

The Board announces that, with effect from December 16, 2022:

- (1) Dr. Lynch has retired from his office as an executive director and CMO of the Company while continue to serve as a consultant; and
- (2) Dr. Zhang has been appointed as CMO of the Company.

RETIREMENT OF EXECUTIVE DIRECTOR AND CMO

The board of directors (the “**Board**”) of Antengene Corporation Limited (the “**Company**”) announces that due to retirement, Dr. Kevin Patrick Lynch (“**Dr. Lynch**”) has tendered his resignation from his office as an executive director and Chief Medical Officer (“**CMO**”) of the Company while continue to serve as a consultant of the Company with effect from December 16, 2022.

Dr. Lynch has confirmed that (i) he has no disagreement with the Board; and (ii) there are no matters with respect to his retirement that need to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

The Board expresses its appreciation to Dr. Lynch for his contributions to the Board during his tenure of services with the Company.

APPOINTMENT OF CMO

In addition, the Board is pleased to announce Dr. Xiaojing Zhang (“**Dr. Zhang**”) will join the Company as CMO, effective from December 16, 2022, directly reporting to Dr. Jay Mei, Founder, Chairman and Chief Executive Officer of the Company. In this role, Dr. Zhang will be responsible for the global clinical development strategy and medical team development and based in Shanghai and New Jersey.

The biographical details of Dr. Zhang are set out below:

Dr. Zhang is a medical oncologist and hematologist with more than 20 years of experience in the field of oncology and pharmaceutical industry, including 7 years of clinical practice in China, nearly 18 years of experience in all phases of clinical development, as well as medical affairs and over 10 years of experience in team management.

Dr. Zhang worked at worked for Novartis China and Bayer in both the United States and China for over 12 years during which she was promoted to the position of Global Clinical Leader (GCL)-Oncology, contributing to the approval of Exjade® and Nexavar® and the global development of Xofigo® and Stivarga® and several early phase compounds.

Dr. Zhang was most recently the CMO (oncology) and earlier the Vice President, Head of Clinical Development - Oncology, and Corporate Vice President at Hengrui Pharmaceuticals for nearly 3.5 years. Under her leadership, the full functional clinical development team has accomplished multiple Investigational New Drug (IND) approvals in both China and US and numerous New Drug Application (NDA) approvals in China. Dr. Zhang will work closely with Dr. Lynch and complete the handover by end of this year on development strategies, clinical projects, and team development.

The Board would like to take this opportunity to welcome Dr. Zhang in joining the Company.

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, December 7, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Dr. Kan Chen and Mr. Yilun Liu as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.